Seaport Therapeutics宣布,其Glyphago药物的重复给药研究显示出良好的安全性特征,且未观察到与肝脏相关的不良事件。
Seaport Therapeutics宣布,其Glyphago药物的重复给药研究显示出良好的安全性特征,且未观察到与肝脏相关的不良事件。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.